Long-term survival benefit
Web9 de set. de 2024 · Two studies report long-term survival benefits with olaparib in ovarian cancer 9 Sept 2024 ESMO Congress 2024 The PARP inhibitor shows durable clinical benefits in HRD+ patients with advanced disease reinforcing the importance of testing for BRCA mutations and/or HRD status.
Long-term survival benefit
Did you know?
Web31 de ago. de 2024 · Our data confirmed a 30- and 60-day mortality benefit following 5-day RDV treatment in severe COVID-19 pneumonia. According to our data, more severe cases, especially men, COPD patients and patients with multiple comorbidities in the need of oxygen support, should receive 5-day RDV as better long-term outcome can be assumed. Web17 de mar. de 2024 · In the current study, the long-term survival benefit of preRT was confirmed using population-based analysis of 7582 LARC patients, which confirmed our …
WebClinical factors influencing long-term survival in a real-life cohort of early stage non-small-cell lung cancer patients in Spain Maria Torrente , 1 , 2 , * † Pedro A. Sousa , 3 , † Gracinda R. Guerreiro , 4 † Fabio Franco , 1 Roberto Hernández , 1 Consuelo Parejo , 1 Alexandre Sousa , 3 José Luis Campo-Cañaveral , 5 João Pimentão , 3 , † and Mariano Provencio … WebPurpose: Dose-escalated (DE) radiotherapy in the setting of localized prostate cancer has been shown to improve biochemical disease-free survival (bDFS) in several studies. In the same group of patients, androgen deprivation therapy (ADT) has been shown to confer a survival benefit when combined with radiotherapy doses of up to 70 Gy; however ...
Web23 de nov. de 2024 · Previous analyses demonstrating the survival benefit of eculizumab in patients with PNH leveraged historical data and were limited by small patient numbers … WebHá 2 dias · According to results presented at the European Lung Cancer Congress 2024 (Copenhagen, 29 March–1 April), long-term analysis of the phase III CheckMate 816 trial (at a median follow-up of 41.4 months) demonstrated that neoadjuvant nivolumab plus platinum doublet chemotherapy prolonged event-free survival (EFS) compared with …
WebData suggest that metabolic and bariatric surgery, in addition to reducing all-cause mortality, may improve survival and longevity. In light of these findings and the unmet need of obesity treatment, ongoing efforts to reduce barriers to access to metabolic and bariatric surgery are necessary. Obesity and mortality
Web12 de abr. de 2024 · The long-term overall survival benefit with atezolizumab over docetaxel was observed across histology (squamous and non-squamous) and … tko je prijavljen na mojoj adresiWeb19 de nov. de 2024 · Long-term OS benefit observed with nivolumab plus ipilimumab in previously untreated patients with advanced NSCLC in this pooled analysis is consistent with long-term survival observed with dual immunotherapy regimens across other tumor types, including untreated advanced melanoma (minimum follow-up, 7.5 years) and … tko je prvi priznao hrvatskuWeb1 de out. de 2024 · Long-term data suggest that achieving a CR is not necessary for a sustained survival benefit, although patients who achieve a CR have more durable benefit over time. 15 53 63 In the COMBI-d and COMBI-v pooled analysis, the 5-year OS rates were 71% in patients with a CR, 32% in patients with a PR, and 16% in patients with SD. … tko je pedro iz plesa sa zvijezdamaWebLong-term survival benefit of ramipril in patients with acute myocardial infarction complicated by heart failure. For patients with clinically defined heart failure following AMI, ramipril results in a sustained survival benefit, and is associated with an extension of life of up to 14.5 months for, on average, 13 months treatment duration. tko je raquel mauriWebConclusion: The pooled data showed high ligation of IMA has a better survival benefit for the patients with IMA positive LNs. It signifies high ligation should be recommended for the advanced cases or with the suspected high risk of IMA lymphatic metastasis. tko je prvi hrvatski kraljWeb1 de jan. de 2024 · Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. Author links open overlay panel Nico Gagelmann 1 Rashit Bogdanov 2 Friedrich Stölzel 3 Christina Rautenberg 4 Victoria Panagiota 5 Heiko Becker 6 Aleksandar Radujkovic 7 Thomas Luft 7 Maximilian … tko je petra iz braka na prvuWeb20 de mai. de 2014 · Methods: A retrospective analysis was performed at the Cliniques Universitaires Saint-Luc to assess the long term survival benefit from ipilimumab treatment in previously treated MUM patients. The patients progressing after a first-line chemotherapy were sequentially included if their ECOG score was ≤ 2. tko je prvi priznao kosovo